Co-Diagnostics

Co-Diagnostics EPS Growth

The EPS Growth of Co-Diagnostics (CODX) as of Nov 20, 2026 is -3.20 %. In the previous year, EPS Growth was -0.75 % — a change of 329.53% (lower).

EPS Growth

-3.20 %

YoY

329.53%

Last updated:

EPS Growth of Co-Diagnostics is 2025 -3.20 % . EPS Growth of Co-Diagnostics was 2024 -0.75 % . It decreases by 329.53% lower compared to the previous year.

The Co-Diagnostics EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2018
97.70 USD
Jan 1, 2019
-1,986.43 USD
Jan 1, 2020
657.16 USD
Jan 1, 2021
-19.09 USD
Jan 1, 2022
-137.68 USD
Jan 1, 2023
-145.08 USD
Jan 1, 2024
-0.75 USD
Jan 1, 2025
-3.20 USD
The Co-Diagnostics EPS Growth history
YEAREPS GrowthYoY
-3.20 %+329.53%
-0.75 %-99.49%
-145.08 %+5.38%
-137.68 %+621.37%
-19.09 %-102.90%
657.16 %-133.08%
-1,986.43 %-2,133.26%
97.70 %-143.61%
-224.01 %-1,268.37%
19.17 %-100.75%
-2,561.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

EPS Growth of Co-Diagnostics is -3.20 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Co-Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Co-Diagnostics

All Key Metrics — Co-Diagnostics